Evidence map›Paper›PMID 28321511›Full record

ArticleVirchows Archiv : an international journal of pathology2017

Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease.

Alessandro Pileri, Claudio Agostinelli, Maurizio Sessa, Pietro Quaglino, Marco Santucci, Carlo Tomasini, Vieri Grandi, Paolo Fava, Chiara Astrua, Simona Righi and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. TOX Expression in Mycosis Fungoides and Sezary Syndrome.Diagnostics (Basel, Switzerland) · 2022
    Article
  5. Article
  6. Article
  7. Review
  8. Tumor-infiltrating and circulating granulocytic myeloid-derived suppressor cells correlate with disease activity and adverse clinical outcomes in mycosis fungoides.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Article
  9. Review
  10. The role of myeloid derived suppressor cells in mycosis fungoides.Cancer immunology, immunotherapy : CII · 2018
    Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alessandro PileriDermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Via Massarenti 1, 40138, Bologna, Italy. alessandropileri@hotmail.it.ORCID http://orcid.org/0000-0002-1025-7171
Claudio AgostinelliHaematopathology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Maurizio SessaDepartment of Experimental Medicine, Section of Pharmacology L. Donatelli, Second University of Naples, Naples, Italy.
Pietro QuaglinoDermatology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.
Marco SantucciDivision of Anatomic Pathology, Department of Surgery and Translational Medicine, University of Florence Medical School, Florence, Italy.
Carlo TomasiniDermatopathology Section, Azienda Ospedaliera Città della Salute e della Scienza, University of Turin, Turin, Italy.
Vieri GrandiDermatology Unit, Department of Surgery and Translational Medicine, University of Florence Medical School, Florence, Italy.
Paolo FavaDermatology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.
Chiara AstruaDermatology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.
Simona RighiHaematopathology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Annalisa PatriziDermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Via Massarenti 1, 40138, Bologna, Italy.
Stefano A PileriUnit of Diagnostic Haematopathology, European Institute of Oncology, Milan, Italy.
Nicola PimpinelliDermatology Unit, Department of Surgery and Translational Medicine, University of Florence Medical School, Florence, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mycosis fungoides (MF) is characterized by a switch from indolent behaviour in the early stages to a worse clinical outcome in the advanced ones. Recently, various studies have investigated the role the microenvironment might play in such a switch. We have analysed the distribution of Langerhans cells, plasmacytoid dendritic cells and myeloid-derived suppressor cells in 46 MF cases in various stages, aiming to assess whether changes occur from early to advanced stage. We have investigated the number of langerin, CD303 and arginase-1 positive cells and their distribution at high power. Data were analysed using t test for continuous variables, χ

Indexed as

AdultAgedDendritic CellsDisease ProgressionFemaleHumansLangerhans CellsMaleMiddle AgedMycosis FungoidesMyeloid-Derived Suppressor CellsSkin NeoplasmsDendritic cellImmunohistochemistryMycosis fungoidesMyeloid-derived suppressor cell

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.